ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
103,582.82
-0.52%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Akebia Therapeutics Inc (AKBA)

  7. Akebia Therapeutics Inc (AKBA) 뉴스

Akebia Therapeutics Inc

Akebia Therapeutics Inc (AKBA)

NASDAQ
2.07
0.14
(7.25%)
마감 18 1월 6:00AM
15분 지연
2.08
0.01
(0.48%)
시간외 거래: 9:50AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

AKBA 뉴스

공식 뉴스 전용

Form 8-K - Current report
Edgar (US Regulatory)
13 1월 2025
AKBA (7.25%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
09 11월 2024
AKBA (7.25%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 11월 2024
AKBA (7.25%)

Form 8-K - Current report
Edgar (US Regulatory)
07 11월 2024
AKBA (7.25%)

AKBA Discussion

게시물 보기
glenn1919 glenn1919 3 일 전
akba........................https://stockcharts.com/h-sc/ui?s=akba&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 일 전
AKBA.............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 일 전
AKBA.................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 월 전
AKBA.....................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
AKBA BIO BEAST INTO FDA
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
AKBA BEASTING LONG...FDA APPROVED DRUG COMES TO MARKET IN JAN
👍️0
TrendTrade2016 TrendTrade2016 3 월 전
AKBA BUILDING 1.79 BREAK IS COMING
👍️0
TrendTrade2016 TrendTrade2016 3 월 전
AKBA GAPPING AND READY FOR 1.79
👍️0
TrendTrade2016 TrendTrade2016 3 월 전
AKBA BACK IN PLAY UNTIL JAN 2025...FDA COMING
👍️0
glenn1919 glenn1919 5 월 전
AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 월 전
AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 월 전
AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 월 전
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Krspecialized Krspecialized 6 월 전
I believe the current news releases may have answered your question. GLTA
👍️0
Toofuzzy Toofuzzy 7 월 전
Why do you say we have a gold mine here ?

Toofuzzy
👍️0
Krspecialized Krspecialized 8 월 전
There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
👍️0
eyeownu eyeownu 8 월 전
SCARY MOVIE
👍️0
eyeownu eyeownu 8 월 전
https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
👍️0
eyeownu eyeownu 8 월 전
added 2k@ 1.11
👍️ 1
glenn1919 glenn1919 9 월 전
AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 월 전
AKBA under $2

👍️0
eyeownu eyeownu 9 월 전
ask is stacked! someone needs to slap it.
👍️0
eyeownu eyeownu 9 월 전
$AKBA RELOAD
👍️0
Firestorm22 Firestorm22 9 월 전
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
Firestorm22 Firestorm22 9 월 전
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
ErnieBilco ErnieBilco 10 월 전
I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
👍️ 1
Firestorm22 Firestorm22 10 월 전
Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
👍️ 1
ErnieBilco ErnieBilco 10 월 전
Classic sell the news. Probable offering coming next week to dilute on the good news.
👍️0
Firestorm22 Firestorm22 10 월 전
Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
👍️0
Krspecialized Krspecialized 10 월 전
Long solid position here!
👍️0
Limey42 Limey42 10 월 전
Long term play. Congrats all!
👍️ 1
dugie100 dugie100 10 월 전
Something didn’t look good , I guess!
👍️0
TrendTrade2016 TrendTrade2016 10 월 전
AKBA should see 3 bucks
👍️0
TrendTrade2016 TrendTrade2016 10 월 전
AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
👍️0
glenn1919 glenn1919 10 월 전
AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 월 전
AKBA new 52 hi
👍️0
eyeownu eyeownu 10 월 전
$AKBA looking good damn! she fine.
👍️ 1
glenn1919 glenn1919 10 월 전
AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 10 월 전
$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
👍️ 1
Monksdream Monksdream 11 월 전
AKBA 10Q March 4
👍️0
Tyrus603 Tyrus603 11 월 전
Excellent chart. Thank you for posting.

Found myself studying it for quite a bit.

As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
👍️0
glenn1919 glenn1919 11 월 전
AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 11 월 전
$AKBA
👍️0
eyeownu eyeownu 11 월 전
$AKBA reversal incoming?
👍️0
eyeownu eyeownu 12 월 전
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
👍️0
eyeownu eyeownu 12 월 전
$AKBA profit taking! hope you took some off the table!
👍️0
eyeownu eyeownu 12 월 전
PDUFA explanation https://www.fool.com/terms/p/pdufa-date/

What percentage of PDUFA are approved?
Characteristic Percentage of drugs approved in 2023
Met PDUFA goal date* 89%
First cycle of review 84%
Approved in the United States before receiving approval in any other country 64%
Priority review 56%

From
👍️0
eyeownu eyeownu 12 월 전
$AKBA via stocktwit @Bidzill @fresh10 fresh - We have PDUFA date scheduled for March 27, 2024 concerning Vadadustat DD USA. Approval is de-risked and highly likely, IMO. We have product launch date first half of year for Vadadustat DD EU/Australia. We have phase 2 trial for AKB 9090 for second half of 2024. We have Auryxia all time/near all time high sales 2024. Good luck 🍀 to you and us.
👍️0
eyeownu eyeownu 12 월 전
https://www.tradingview.com/x/6Ykwijbc/
👍️0
eyeownu eyeownu 12 월 전
$AKBA from stocktwits

MORE GOOD NEWS - FDA Fast Track Designation is process designed to facilitate development & expedite drug review to treat serious conditions & fill UNMET MEDICAL NEED. Determining whether condition is serious enough for designation is matter of judgment … ARDS is life threatening & acute, diffuse, inflammatory form of lung injury in seriously ill patients characterized by poor oxygenation, pulmonary infiltrates, acute onset. Unadjusted hospitalization mortality was reported to be 35% among those w/ mild ARDS, 40% w/ moderate disease, 46% for patients w/ severe ARDS. AKB 9090 is Akebia’s ARDS drug. Filling an unmet need is defined as providing therapy where none exists or which may be potentially better than available therapy. Drug that receives Fast Track is eligible for accelerated approval/priority review. August of 2022, CEO Butler said Vadadustat was in trials for Covid-19/ARDS which was an “unmet medical need.” Butler was signaling intention to go after Fast Track status.
https://stocktwits.com/buythehornz127/message/559186953
👍️0

최근 히스토리

NASDAQ
AKBA
Akebia Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유